China Regulator Accepts Akeso, Sino Biopharm Application For Cancer Drug

China Regulator Accepts Akeso, Sino Biopharm Application For Cancer Drug

News

The Hong Kong Stock Exchange has attracted a growing number of China biotech and pharmaceutical … [+] companies in recent years. Photographer: Paul Yeung/Bloomberg

© 2021 Bloomberg Finance LP

China’s National Medical Products Administration has accepted a new drug application from mainland pharmaceutical suppliers Akeso and Sino Biopharmaceutical for treatment of nasopharygeal cancer, or NPC.

Hong Kong-traded shares in both companies rose after the announcement this morning, though fell back later amid a broader selloff amid concerns on the spread of the Delta variant in the mainland. (See Akeso announcement here.)

China, the world’s most populous nation, had 4.6 million new cancer cases last year, according to Statista. A growing number of cases has made the country one of the world’s largest markets for cancer drugs.   Top cancers in China are lung, colorectum, stomach, breast and liver, Statista says.

NPC, a type of head and neck cancer,  starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull, according to a description by the American Cancer Society.  Cancer starts when cells begin to grow out of control, it noted.

Rare in most parts of the world, NPC is more common in certain parts of South Asia, the Middle East, and North Africa. In some parts of China there are as many as 21 cases per 100,000 people, the American Cancer Society said.

Global collaboration in the fight against cancer will be a theme of the 2021 Forbes China Healthcare Summit to be held online on Aug. 27. For more information, contact me at Kelly.ang@forbeschina.com.

See related posts:

Cancer Fight Shows Way For U.S., China To Cool Off, Collaborate: Kevin Rudd

How Int’l Collaboration Is Winning A Flight Bigger Than Covid-19

@rflannerychina

Binance

Source link

Latest Crypto News


Popular Links

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments